DOI: 10.12890/2025_005822
Uncontrolled Graves’ disease as a driver of amplified warfarin sensitivity
Authors
esraaaockba@gmail.com
Keywords
Warfarin, INR, hyperthyroidism, anticoagulationAbstract
Background: Thyroid function abnormalities can alter the pharmacokinetics of various drugs, including warfarin. Although a few case reports in the literature have highlighted this phenomenon, ours is the first in the region.
Case description: We report a case of a 40-year-old female known to have uncontrolled Graves’ disease due to non-compliance with medication and follow-up, with a history of mitral valve replacement, on warfarin 3 mg daily. She presented with a headache and was found to have a subdural haematoma and an INR of 10.58. It was observed that as she was approaching euthyroid state with antithyroid treatment; her warfarin requirement slowly increased to maintain the target INR.
Conclusion: Our case highlights the relationship between hyperthyroidism and exaggerated response to vitamin K antagonists. Literature suggests there is an amplified response to warfarin in a hyperthyroid state. Therefore, a timely and close follow-up of INR and thyroid function test is warranted in patients with hyperthyroidism on anti-coagulation with warfarin.
References
- Erem C. Thyroid disorders and hypercoagulability. Semin Thromb Hemost 2011;37:17–26. doi:10.1055/s-0030-1270067
- Elbers LPB, Fliers E, Cannegieter SC. The influence of thyroid function on the coagulation system and its clinical consequences. J Thromb Haemos 2018;16:634–645. doi: 10.1111/jth.13970
- Antonijevic N, Matic D, Beleslin B, Mikovic D, Lekovic Z, Marjanovic M, et al. The influence of hyperthyroidism on the coagulation and on the risk of thrombosis. J Clin Med 2024;13:1756. doi:10.3390/jcm13061756
- Howard-Thompson A, Luckey A, George C, Choby BA, Self TH. Graves’ disease and treatment effects on warfarin anticoagulation. Case Rep Med 2014;2014:292468. doi: 10.1155/2014/292468
- Akin F, Yaylali GF, Bastemir M, Yapar B. Effect of methimazole on warfarin anticoagulation in a case of Graves’ disease. Blood Coagul Fibrinolysis 2008;19:89–91. doi: 10.1097/MBC.0b013e3282f0981f
- Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S–198S. doi: 10.1378/chest.08-0670
- Lee JE, Ryu DH, Jeong HJ, Kim JH, Jun JE, Kim JS, et al. Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis. J Korean Med Sci 2014;29:1317–1319. doi:10.3346/jkms.2014.29.9.1317
- Wang M, Zeraatkar D, Obeda M, et al. Drug–drug interactions with warfarin: A systematic review and meta-analysis. Br J Clin Pharmacol 2021;87:4051–4100. doi: 10.1111/bcp.14833
- Lilihata G, Saputra C, Yaniarti D, Soerarso R. Hyperthyroidism in severe mitral regurgitation post mechanical mitral valve replacement: the effect on warfarin anticoagulation. Cardiovasc Endocrinol Metab 2020;10:146–148. doi: 10.1097/XCE.0000000000000233
- Bucerius J, Ezziddin S, Brockmann H, Palmedo H, Biersack HJ. Impact of thyroid metabolism on the course of INR levels in a patient with systemic anticoagulation suffering from amiodarone-induced thyrotoxicosis. Exp Clin Endocrinol Diabetes 2007;115:606-609. doi: 10.1055/s-2007-984439
- Busenbark LA, Cushnie SA. Effect of Graves’ disease and methimazole on warfarin anticoagulation. Ann Pharmacother 2006;40:1200–1203. doi: 10.1345/aph.1G422
- Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary. A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;143. doi: 10.1161/CIR.0000000000000923
